McCann FitzGerald advises Horizon Pharma plc on its $400 million Exchangeable Senior Note offering

We acted as Irish counsel to Horizon Pharma plc in relation to its offering of $400 million aggregate principal amount of 2.50% Exchangeable Senior Notes due 2022 in a private placement to qualified institutional buyers pursuant to Rule 144A under the US Securities Act of 1933.